Autologous CD19-directed CAR-T cells
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for Autologous CD19-directed CAR-T cells, covering 2016-01-01 to 2016-01-01. Get the full timeline:
Most recent: Clinical Trial Update: Immunotherapy Using Autologous T Cell-Engineered With CD19-specific Chimeric Antigen Receptor for the Treatment of Recurrent /Refractory B Cell Leukemia [Phase 1, Phase 2]